{"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"name":"python","version":"3.11.11","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"},"kaggle":{"accelerator":"none","dataSources":[],"dockerImageVersionId":31012,"isInternetEnabled":true,"language":"python","sourceType":"notebook","isGpuEnabled":false}},"nbformat_minor":4,"nbformat":4,"cells":[{"cell_type":"code","source":"# üì¶ Install Biopython (if not already installed)\n!pip install biopython","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-05-05T05:27:38.649589Z","iopub.execute_input":"2025-05-05T05:27:38.649804Z","iopub.status.idle":"2025-05-05T05:27:42.220790Z","shell.execute_reply.started":"2025-05-05T05:27:38.649786Z","shell.execute_reply":"2025-05-05T05:27:42.219732Z"},"collapsed":true,"jupyter":{"outputs_hidden":true}},"outputs":[{"name":"stdout","text":"Requirement already satisfied: biopython in /usr/local/lib/python3.11/dist-packages (1.85)\nRequirement already satisfied: numpy in /usr/local/lib/python3.11/dist-packages (from biopython) (1.26.4)\nRequirement already satisfied: mkl_fft in /usr/local/lib/python3.11/dist-packages (from numpy->biopython) (1.3.8)\nRequirement already satisfied: mkl_random in /usr/local/lib/python3.11/dist-packages (from numpy->biopython) (1.2.4)\nRequirement already satisfied: mkl_umath in /usr/local/lib/python3.11/dist-packages (from numpy->biopython) (0.1.1)\nRequirement already satisfied: mkl in /usr/local/lib/python3.11/dist-packages (from numpy->biopython) (2025.1.0)\nRequirement already satisfied: tbb4py in /usr/local/lib/python3.11/dist-packages (from numpy->biopython) (2022.1.0)\nRequirement already satisfied: mkl-service in /usr/local/lib/python3.11/dist-packages (from numpy->biopython) (2.4.1)\nRequirement already satisfied: intel-openmp<2026,>=2024 in /usr/local/lib/python3.11/dist-packages (from mkl->numpy->biopython) (2024.2.0)\nRequirement already satisfied: tbb==2022.* in /usr/local/lib/python3.11/dist-packages (from mkl->numpy->biopython) (2022.1.0)\nRequirement already satisfied: tcmlib==1.* in /usr/local/lib/python3.11/dist-packages (from tbb==2022.*->mkl->numpy->biopython) (1.2.0)\nRequirement already satisfied: intel-cmplr-lib-rt in /usr/local/lib/python3.11/dist-packages (from mkl_umath->numpy->biopython) (2024.2.0)\nRequirement already satisfied: intel-cmplr-lib-ur==2024.2.0 in /usr/local/lib/python3.11/dist-packages (from intel-openmp<2026,>=2024->mkl->numpy->biopython) (2024.2.0)\n","output_type":"stream"}],"execution_count":9},{"cell_type":"code","source":"# üìö Import required library\nfrom Bio import Entrez\n\n# üìß Set email for NCBI Entrez access\nEntrez.email = \"sheetal.reddy@g.austincc.edu\"","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-05-05T05:27:42.222075Z","iopub.execute_input":"2025-05-05T05:27:42.222657Z","iopub.status.idle":"2025-05-05T05:27:42.227690Z","shell.execute_reply.started":"2025-05-05T05:27:42.222615Z","shell.execute_reply":"2025-05-05T05:27:42.226788Z"}},"outputs":[],"execution_count":10},{"cell_type":"code","source":"# üîé Step 1: List all available Entrez databases\nhandle = Entrez.einfo()\nrecord = Entrez.read(handle)\nrecord[\"DbList\"]","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-05-05T05:27:42.228742Z","iopub.execute_input":"2025-05-05T05:27:42.229127Z","iopub.status.idle":"2025-05-05T05:27:42.535569Z","shell.execute_reply.started":"2025-05-05T05:27:42.229099Z","shell.execute_reply":"2025-05-05T05:27:42.534754Z"}},"outputs":[{"execution_count":11,"output_type":"execute_result","data":{"text/plain":"['pubmed', 'protein', 'nuccore', 'ipg', 'nucleotide', 'structure', 'genome', 'annotinfo', 'assembly', 'bioproject', 'biosample', 'blastdbinfo', 'books', 'cdd', 'clinvar', 'gap', 'gapplus', 'grasp', 'dbvar', 'gene', 'gds', 'geoprofiles', 'medgen', 'mesh', 'nlmcatalog', 'omim', 'orgtrack', 'pmc', 'proteinclusters', 'pcassay', 'protfam', 'pccompound', 'pcsubstance', 'seqannot', 'snp', 'sra', 'taxonomy', 'biocollections', 'gtr']"},"metadata":{}}],"execution_count":11},{"cell_type":"code","source":"# üîç Step 2: Explore metadata about the PubMed database\nhandle = Entrez.einfo(db=\"pubmed\")\nrecord = Entrez.read(handle)\n\n# View top-level keys\nprint(\"Top-level keys:\", list(record.keys()))\nprint(\"\\n\")\n# View database information keys\nprint(\"DbInfo keys:\", list(record[\"DbInfo\"].keys()))\nprint(\"\\n\")\n# Print database description and number of records\nprint(\"Description:\", record[\"DbInfo\"][\"Description\"])\nprint(\"Total Records:\", record[\"DbInfo\"][\"Count\"])\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-05-05T05:27:42.536583Z","iopub.execute_input":"2025-05-05T05:27:42.536855Z","iopub.status.idle":"2025-05-05T05:27:43.077880Z","shell.execute_reply.started":"2025-05-05T05:27:42.536824Z","shell.execute_reply":"2025-05-05T05:27:43.077069Z"}},"outputs":[{"name":"stdout","text":"Top-level keys: ['DbInfo']\n\n\nDbInfo keys: ['DbName', 'MenuName', 'Description', 'DbBuild', 'Count', 'LastUpdate', 'FieldList', 'LinkList']\n\n\nDescription: PubMed bibliographic record\nTotal Records: 38766138\n","output_type":"stream"}],"execution_count":12},{"cell_type":"code","source":"# üß¨ Step 3: Search PubMed for the TP53 gene\nhandle = Entrez.esearch(db=\"pubmed\", term=\"TP53\")\nrecord = Entrez.read(handle)\n\n# View structure and result IDs\nprint(\"Search record keys:\", list(record.keys()))\nprint(\"\\n\")\nprint(\"Found IDs:\", record[\"IdList\"])","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-05-05T05:27:43.078731Z","iopub.execute_input":"2025-05-05T05:27:43.078983Z","iopub.status.idle":"2025-05-05T05:27:43.460533Z","shell.execute_reply.started":"2025-05-05T05:27:43.078966Z","shell.execute_reply":"2025-05-05T05:27:43.459778Z"}},"outputs":[{"name":"stdout","text":"Search record keys: ['Count', 'RetMax', 'RetStart', 'IdList', 'TranslationSet', 'QueryTranslation']\n\n\nFound IDs: ['40320401', '40320171', '40319323', '40319042', '40319028', '40319021', '40318009', '40316697', '40315632', '40315418', '40314902', '40314231', '40313151', '40313121', '40312921', '40312368', '40311763', '40311718', '40311467', '40311321']\n","output_type":"stream"}],"execution_count":13},{"cell_type":"code","source":"# üìÑ Step 4: Get article summaries for two sample PMIDs\nhandle = Entrez.esummary(db=\"pubmed\", id=\"40320401,40320171\")\nrecords = Entrez.parse(handle)\n\n# üñãÔ∏è Optional: Format with bold/underline styling (works in terminal and notebooks that support ANSI)\nbold = \"\\033[1m\"\nunderline = \"\\033[4m\"\nreset = \"\\033[0m\"\n\nfor i, record in enumerate(records, 1):\n    print(f\"{bold}Record {i}:{reset}\\n\")\n    print(f\"{bold}{underline}Authors:{reset}\", record[\"AuthorList\"])\n    print(f\"{bold}{underline}Title:{reset}\", record[\"Title\"])\n    print(f\"{bold}{underline}Publication Date:{reset}\", record[\"PubDate\"])\n    print(f\"{bold}{underline}Journal:{reset}\", record[\"FullJournalName\"])\n    print(\"\\n\")\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-05-05T05:32:14.972634Z","iopub.execute_input":"2025-05-05T05:32:14.972988Z","iopub.status.idle":"2025-05-05T05:32:15.316959Z","shell.execute_reply.started":"2025-05-05T05:32:14.972953Z","shell.execute_reply":"2025-05-05T05:32:15.316164Z"}},"outputs":[{"name":"stdout","text":"\u001b[1mRecord 1:\u001b[0m\n\n\u001b[1m\u001b[4mAuthors:\u001b[0m ['Li Y', 'Song C', 'Wang H', 'Di W', 'Chen Y', 'Hu Y', 'Li P', 'Chen J', 'Ren Y', 'Gong J', 'Wang Q']\n\u001b[1m\u001b[4mTitle:\u001b[0m Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications.\n\u001b[1m\u001b[4mPublication Date:\u001b[0m 2025 May 4\n\u001b[1m\u001b[4mJournal:\u001b[0m Scientific reports\n\n\n\u001b[1mRecord 2:\u001b[0m\n\n\u001b[1m\u001b[4mAuthors:\u001b[0m ['Sabari JK', 'Yu HA', 'Mahadevia PJ', 'Liu Y', 'Demirdjian L', 'Chen YH', 'Wang X', 'Passaro A']\n\u001b[1m\u001b[4mTitle:\u001b[0m Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.\n\u001b[1m\u001b[4mPublication Date:\u001b[0m 2025 May 2\n\u001b[1m\u001b[4mJournal:\u001b[0m Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\n\n\n","output_type":"stream"}],"execution_count":17},{"cell_type":"code","source":"# üßæ Step 5: Fetch raw XML for a specific article and pretty-print it\nimport xml.dom.minidom\n\nhandle = Entrez.efetch(db=\"pubmed\", id=\"40319323\", retmode=\"xml\")\nraw_xml = handle.read()\n\nparsed_xml = xml.dom.minidom.parseString(raw_xml)\npretty_xml = parsed_xml.toprettyxml(indent=\"  \")\n\nprint(pretty_xml)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-05-05T05:32:42.558164Z","iopub.execute_input":"2025-05-05T05:32:42.558962Z","iopub.status.idle":"2025-05-05T05:32:43.037590Z","shell.execute_reply.started":"2025-05-05T05:32:42.558925Z","shell.execute_reply":"2025-05-05T05:32:43.036849Z"}},"outputs":[{"name":"stdout","text":"<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet\n  PUBLIC '-//NLM//DTD PubMedArticle, 1st January 2025//EN'\n  'https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd'>\n<PubmedArticleSet>\n  \n\n  <PubmedArticle>\n    <MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\">\n      <PMID Version=\"1\">40319323</PMID>\n      <DateRevised>\n        <Year>2025</Year>\n        <Month>05</Month>\n        <Day>03</Day>\n      </DateRevised>\n      <Article PubModel=\"Electronic\">\n        <Journal>\n          <ISSN IssnType=\"Print\">1475-2867</ISSN>\n          <JournalIssue CitedMedium=\"Print\">\n            <Volume>25</Volume>\n            <Issue>1</Issue>\n            <PubDate>\n              <Year>2025</Year>\n              <Month>May</Month>\n              <Day>03</Day>\n            </PubDate>\n          </JournalIssue>\n          <Title>Cancer cell international</Title>\n          <ISOAbbreviation>Cancer Cell Int</ISOAbbreviation>\n        </Journal>\n        <ArticleTitle>Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma.</ArticleTitle>\n        <Pagination>\n          <StartPage>172</StartPage>\n          <MedlinePgn>172</MedlinePgn>\n        </Pagination>\n        <ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12935-025-03789-9</ELocationID>\n        <Abstract>\n          <AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin's lymphoma. The applicability of circulating tumor DNA (ctDNA) for predicting treatment response and prognosis in MCL remains underexplored.</AbstractText>\n          <AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This study included 34 MCL patients receiving first-line chemoimmunotherapy. We assessed the ability of plasma ctDNA to detect tumor-specific genetic alterations and explored its potential as a noninvasive biomarker for treatment response and prognosis in MCL.</AbstractText>\n          <AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Commonly mutated genes in MCL included CCND1 (93.5%), ATM (48.4%), KMT2D (25.8%), and TP53 (25.8%). Subgroup analysis of tissue samples showed that CDKN2A mutations (P‚Äâ=‚Äâ0.028), along with alterations in BCR and TCR signaling (P‚Äâ=‚Äâ0.004) and the PI3K pathway (P‚Äâ=‚Äâ0.008), were enriched in the blastoid subtype. ATM mutations (P‚Äâ=‚Äâ0.041) were more prevalent in MIPI-low patients, while epigenetic chromatin remodeling pathway alterations (P‚Äâ=‚Äâ0.028) were more common in MIPI-high patients. Plasma ctDNA demonstrated high sensitivity for detecting structural variants (96.6%), followed by mutations (71.3%) and copy number variants (30.0%). 75% of patients exhibited moderate-to-high concordance in detecting genomic variants between plasma and tissue samples. Pretreatment ctDNA levels exhibited high specificity in predicting clinical efficacy but had a suboptimal sensitivity of 68.2%. Higher ctDNA levels were significantly associated with shorter progression-free survival (PFS; P‚Äâ=‚Äâ0.002) and overall survival (OS; P‚Äâ=‚Äâ0.009). Additional ctDNA-based genetic features associated with shorter PFS included TP53 (P‚Äâ=‚Äâ0.002), TRAF2 (P‚Äâ=‚Äâ0.023), and SMARCA4 (P‚Äâ=‚Äâ0.023) mutations, while TP53 (P‚Äâ=‚Äâ0.006) and TERT (P‚Äâ=‚Äâ0.031) mutations predicted shorter OS. Persistent positive ctDNA in post-treatment plasma samples indicated molecular relapse and poor prognosis, whereas undetectable ctDNA defined a subset of patients with favorable survival outcomes.</AbstractText>\n          <AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">This study identified plasma ctDNA as a promising biomarker that noninvasively captures tumor-derived genetic variants associated with treatment response and survival outcomes in MCL, highlighting the clinical value of ctDNA for diagnosis, recurrence prediction, and surveillance monitoring.</AbstractText>\n          <CopyrightInformation>¬© 2025. The Author(s).</CopyrightInformation>\n        </Abstract>\n        <AuthorList CompleteYN=\"Y\">\n          <Author ValidYN=\"Y\" EqualContrib=\"Y\">\n            <LastName>Ouyang</LastName>\n            <ForeName>Zhou</ForeName>\n            <Initials>Z</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013, Hunan, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\" EqualContrib=\"Y\">\n            <LastName>Zeng</LastName>\n            <ForeName>Ruolan</ForeName>\n            <Initials>R</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013, Hunan, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Wang</LastName>\n            <ForeName>Song</ForeName>\n            <Initials>S</Initials>\n            <AffiliationInfo>\n              <Affiliation>Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, Jiangsu, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Wu</LastName>\n            <ForeName>Xiaoying</ForeName>\n            <Initials>X</Initials>\n            <AffiliationInfo>\n              <Affiliation>Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, Jiangsu, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Li</LastName>\n            <ForeName>Yajun</ForeName>\n            <Initials>Y</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013, Hunan, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>He</LastName>\n            <ForeName>Yizi</ForeName>\n            <Initials>Y</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013, Hunan, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Wang</LastName>\n            <ForeName>Caiqin</ForeName>\n            <Initials>C</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013, Hunan, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Xia</LastName>\n            <ForeName>Chen</ForeName>\n            <Initials>C</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013, Hunan, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Ou</LastName>\n            <ForeName>Qiuxiang</ForeName>\n            <Initials>Q</Initials>\n            <AffiliationInfo>\n              <Affiliation>Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, Jiangsu, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Bao</LastName>\n            <ForeName>Hua</ForeName>\n            <Initials>H</Initials>\n            <AffiliationInfo>\n              <Affiliation>Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, Jiangsu, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Yang</LastName>\n            <ForeName>Wei</ForeName>\n            <Initials>W</Initials>\n            <AffiliationInfo>\n              <Affiliation>Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, Jiangsu, China.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Xiao</LastName>\n            <ForeName>Ling</ForeName>\n            <Initials>L</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Histology and Embryology, School of Basic Medical Science, Central South University, Changsha, 410013, Hunan, China. xiaolingcsu@csu.edu.cn.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n          <Author ValidYN=\"Y\">\n            <LastName>Zhou</LastName>\n            <ForeName>Hui</ForeName>\n            <Initials>H</Initials>\n            <AffiliationInfo>\n              <Affiliation>Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, 410013, Hunan, China. zhouhui9403@126.com.</Affiliation>\n            </AffiliationInfo>\n          </Author>\n        </AuthorList>\n        <Language>eng</Language>\n        <GrantList CompleteYN=\"Y\">\n          <Grant>\n            <GrantID>No. 82204414</GrantID>\n            <Agency>National Natural Science Foundation of China</Agency>\n            <Country/>\n          </Grant>\n          <Grant>\n            <GrantID>No. 2022JJ30789</GrantID>\n            <Agency>Hunan¬†Provincial¬†Natural¬†Science¬†Foundation¬†of¬†China</Agency>\n            <Country/>\n          </Grant>\n          <Grant>\n            <GrantID>No.¬†2022JJ30026</GrantID>\n            <Agency>Hunan¬†Provincial¬†Natural¬†Science¬†Foundation¬†of¬†China</Agency>\n            <Country/>\n          </Grant>\n          <Grant>\n            <GrantID>[2021]No.1073</GrantID>\n            <Agency>Precision¬†Diagnosis¬†and¬†Treatment¬†Center¬†for¬†Lymphoma¬†in¬†Hunan¬†Province,¬†Hunan¬†Development¬†and¬†Reform¬†Commission¬†High-tech</Agency>\n            <Country/>\n          </Grant>\n          <Grant>\n            <GrantID>No.¬†2021SK4015</GrantID>\n            <Agency>Clinical¬†Research¬†Center¬†for¬†Lymphoma¬†in¬†Hunan¬†Province,¬†Hunan¬†Provincial¬†Clinical¬†Medical¬†Research¬†Center¬†for¬†Lymphatic¬†Tumors</Agency>\n            <Country/>\n          </Grant>\n          <Grant>\n            <GrantID>No. 2023-223</GrantID>\n            <Agency>National¬†Key¬†Clinical¬†Specialty¬†Construction¬†Project</Agency>\n            <Country/>\n          </Grant>\n        </GrantList>\n        <PublicationTypeList>\n          <PublicationType UI=\"D016428\">Journal Article</PublicationType>\n        </PublicationTypeList>\n        <ArticleDate DateType=\"Electronic\">\n          <Year>2025</Year>\n          <Month>05</Month>\n          <Day>03</Day>\n        </ArticleDate>\n      </Article>\n      <MedlineJournalInfo>\n        <Country>England</Country>\n        <MedlineTA>Cancer Cell Int</MedlineTA>\n        <NlmUniqueID>101139795</NlmUniqueID>\n        <ISSNLinking>1475-2867</ISSNLinking>\n      </MedlineJournalInfo>\n      <KeywordList Owner=\"NOTNLM\">\n        <Keyword MajorTopicYN=\"N\">Biomarker</Keyword>\n        <Keyword MajorTopicYN=\"N\">Chemoimmunotherapy</Keyword>\n        <Keyword MajorTopicYN=\"N\">Circulating tumor DNA</Keyword>\n        <Keyword MajorTopicYN=\"N\">Mantle cell lymphoma</Keyword>\n      </KeywordList>\n      <CoiStatement>Declarations. Ethics approval and consent to participate: The study was approved by the Ethics Committee of Hunan Cancer Hospital (No. 2024‚Äì152). Written informed consent was obtained from each patient before sample collection. Consent for publication: Not applicable. Competing interests: S. Wang, X.Y. Wu, Q.X. Ou, H. Bao, and W. Yang are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare no competing interests.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n      <History>\n        <PubMedPubDate PubStatus=\"received\">\n          <Year>2025</Year>\n          <Month>2</Month>\n          <Day>28</Day>\n        </PubMedPubDate>\n        <PubMedPubDate PubStatus=\"accepted\">\n          <Year>2025</Year>\n          <Month>4</Month>\n          <Day>12</Day>\n        </PubMedPubDate>\n        <PubMedPubDate PubStatus=\"medline\">\n          <Year>2025</Year>\n          <Month>5</Month>\n          <Day>4</Day>\n          <Hour>0</Hour>\n          <Minute>46</Minute>\n        </PubMedPubDate>\n        <PubMedPubDate PubStatus=\"pubmed\">\n          <Year>2025</Year>\n          <Month>5</Month>\n          <Day>4</Day>\n          <Hour>0</Hour>\n          <Minute>45</Minute>\n        </PubMedPubDate>\n        <PubMedPubDate PubStatus=\"entrez\">\n          <Year>2025</Year>\n          <Month>5</Month>\n          <Day>3</Day>\n          <Hour>23</Hour>\n          <Minute>28</Minute>\n        </PubMedPubDate>\n      </History>\n      <PublicationStatus>epublish</PublicationStatus>\n      <ArticleIdList>\n        <ArticleId IdType=\"pubmed\">40319323</ArticleId>\n        <ArticleId IdType=\"doi\">10.1186/s12935-025-03789-9</ArticleId>\n        <ArticleId IdType=\"pii\">10.1186/s12935-025-03789-9</ArticleId>\n      </ArticleIdList>\n      <ReferenceList>\n        <Reference>\n          <Citation>Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375‚Äì90.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">26980727</ArticleId>\n            <ArticleId IdType=\"pmc\">4874220</ArticleId>\n            <ArticleId IdType=\"doi\">10.1182/blood-2016-01-643569</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Jain P, Wang ML. Mantle cell lymphoma in 2022‚Äîa comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638‚Äì56.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">35266562</ArticleId>\n            <ArticleId IdType=\"doi\">10.1002/ajh.26523</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Silkenstedt E, Dreyling M. Mantle cell lymphoma-update on molecular biology, prognostication and treatment approaches. Hematol Oncol. 2023;41(Suppl 1):36‚Äì42.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">37294961</ArticleId>\n            <ArticleId IdType=\"doi\">10.1002/hon.3149</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton‚Äôs tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312‚Äì32.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">33122850</ArticleId>\n            <ArticleId IdType=\"doi\">10.1038/s41375-020-01072-6</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Davis DD, Ohana Z, Pham HM. Pirtobrutinib: a novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma. J Oncol Pharm Pract. 2024;30(1):182‚Äì8.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">38043933</ArticleId>\n            <ArticleId IdType=\"doi\">10.1177/10781552231216886</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024;11(9):e682‚Äì92.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">39033770</ArticleId>\n            <ArticleId IdType=\"doi\">10.1016/S2352-3026(24)00172-8</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)‚Äîoutcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623‚Äì9.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">32239765</ArticleId>\n            <ArticleId IdType=\"doi\">10.1002/ajh.25796</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331‚Äì42.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">32242358</ArticleId>\n            <ArticleId IdType=\"pmc\">7731441</ArticleId>\n            <ArticleId IdType=\"doi\">10.1056/NEJMoa1914347</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558‚Äì65.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">17962512</ArticleId>\n            <ArticleId IdType=\"doi\">10.1182/blood-2007-06-095331</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network. Blood. 2018;131(4):417‚Äì20.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">29196411</ArticleId>\n            <ArticleId IdType=\"doi\">10.1182/blood-2017-07-797019</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(45):18250‚Äì5.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">24145436</ArticleId>\n            <ArticleId IdType=\"pmc\">3831489</ArticleId>\n            <ArticleId IdType=\"doi\">10.1073/pnas.1314608110</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903‚Äì10.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">28819011</ArticleId>\n            <ArticleId IdType=\"doi\">10.1182/blood-2017-04-779736</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Yang P, Zhang W, Wang J, Liu Y, An R, Jing H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. 2018;25(5‚Äì6):129‚Äì40.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">29755111</ArticleId>\n            <ArticleId IdType=\"doi\">10.1038/s41417-018-0022-5</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, et al. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015;169(5):689‚Äì93.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">25818067</ArticleId>\n            <ArticleId IdType=\"pmc\">5279064</ArticleId>\n            <ArticleId IdType=\"doi\">10.1111/bjh.13349</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541‚Äì9.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">25842160</ArticleId>\n            <ArticleId IdType=\"pmc\">4460610</ArticleId>\n            <ArticleId IdType=\"doi\">10.1016/S1470-2045(15)70106-3</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">27831904</ArticleId>\n            <ArticleId IdType=\"pmc\">5490494</ArticleId>\n            <ArticleId IdType=\"doi\">10.1126/scitranslmed.aai8545</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947‚Äì57.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">28096087</ArticleId>\n            <ArticleId IdType=\"doi\">10.1182/blood-2016-05-719641</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845‚Äì53.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">30125215</ArticleId>\n            <ArticleId IdType=\"pmc\">6161832</ArticleId>\n            <ArticleId IdType=\"doi\">10.1200/JCO.2018.78.5246</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413‚Äì25.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">29449275</ArticleId>\n            <ArticleId IdType=\"doi\">10.1182/blood-2017-11-812073</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2020;34(1):151‚Äì66.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">31431735</ArticleId>\n            <ArticleId IdType=\"doi\">10.1038/s41375-019-0541-6</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Camus V, Viennot M, Lequesne J, Viailly PJ, Bohers E, Bessi L, et al. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica. 2021;106(1):154‚Äì62.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">32079702</ArticleId>\n            <ArticleId IdType=\"doi\">10.3324/haematol.2019.237719</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059‚Äì68.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">25113753</ArticleId>\n            <ArticleId IdType=\"pmc\">4979083</ArticleId>\n            <ArticleId IdType=\"doi\">10.1200/JCO.2013.54.8800</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114‚Äì20.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">24695404</ArticleId>\n            <ArticleId IdType=\"pmc\">4103590</ArticleId>\n            <ArticleId IdType=\"doi\">10.1093/bioinformatics/btu170</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568‚Äì76.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">22300766</ArticleId>\n            <ArticleId IdType=\"pmc\">3290792</ArticleId>\n            <ArticleId IdType=\"doi\">10.1101/gr.129684.111</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Liu SY, Bao H, Wang Q, Mao WM, Chen Y, Tong X, et al. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun. 2021;12(1):6450.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">34750392</ArticleId>\n            <ArticleId IdType=\"pmc\">8575965</ArticleId>\n            <ArticleId IdType=\"doi\">10.1038/s41467-021-26806-7</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16): e131.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">27270079</ArticleId>\n            <ArticleId IdType=\"pmc\">5027494</ArticleId>\n            <ArticleId IdType=\"doi\">10.1093/nar/gkw520</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Shah Ronak. icallSV: A Framework to call Structural Variants from NGS based datasets. 2017; Available from: https://github.com/rhshah/iCallSV .</Citation>\n        </Reference>\n        <Reference>\n          <Citation>Shah Ronak. iAnnotateSV: Annotation of structural variants detected from NGS. 2021; Available from: https://github.com/rhshah/iAnnotateSV .</Citation>\n        </Reference>\n        <Reference>\n          <Citation>Huang X, He M, Peng H, Tong C, Liu Z, Zhang X, et al. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. J Immunother Cancer. 2021;9(5): e002223.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">34011535</ArticleId>\n            <ArticleId IdType=\"pmc\">8137235</ArticleId>\n            <ArticleId IdType=\"doi\">10.1136/jitc-2020-002223</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Yang Y, Wang J, Wang J, Zhao X, Zhang T, Yang Y, et al. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer. Cancer Lett. 2024;582: 216569.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">38101608</ArticleId>\n            <ArticleId IdType=\"doi\">10.1016/j.canlet.2023.216569</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321‚Äì37.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">29625050</ArticleId>\n            <ArticleId IdType=\"pmc\">6070353</ArticleId>\n            <ArticleId IdType=\"doi\">10.1016/j.cell.2018.03.035</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017:1‚Äì16.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"doi\">10.1200/PO.17.00011</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, et al. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022;107(3):690‚Äì701.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">33792219</ArticleId>\n            <ArticleId IdType=\"doi\">10.3324/haematol.2020.274258</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Zhang X, Yang L, Zhu M, Zhao X, Xiao Y, Pang J, et al. The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas. Future Oncol. 2024;20:1‚Äì11.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"doi\">10.1080/14796694.2024.2402209</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649‚Äì59.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">29650362</ArticleId>\n            <ArticleId IdType=\"doi\">10.1016/S1470-2045(18)30145-1</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Li M, Mi L, Wang C, Wang X, Zhu J, Qi F, et al. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy. BMC Med. 2022;20(1):369.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">36280874</ArticleId>\n            <ArticleId IdType=\"pmc\">9594942</ArticleId>\n            <ArticleId IdType=\"doi\">10.1186/s12916-022-02562-3</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aau1167 .</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"doi\">10.1126/scitranslmed.aau1167</ArticleId>\n            <ArticleId IdType=\"pubmed\">31852798</ArticleId>\n            <ArticleId IdType=\"pmc\">7265335</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol Cancer Ther. 2021;20(12):2341‚Äì51.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">34642211</ArticleId>\n            <ArticleId IdType=\"doi\">10.1158/1535-7163.MCT-21-0433</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119‚Äì29.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">30455436</ArticleId>\n            <ArticleId IdType=\"doi\">10.1038/s41591-018-0243-z</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014;24:30‚Äì7.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">24657534</ArticleId>\n            <ArticleId IdType=\"doi\">10.1016/j.gde.2013.11.005</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193‚Äì204.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">15023437</ArticleId>\n            <ArticleId IdType=\"doi\">10.1016/j.ctrv.2003.07.007</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10(2):103‚Äì6.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">23241902</ArticleId>\n            <ArticleId IdType=\"doi\">10.1038/cmi.2012.61</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507‚Äì16.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">23782157</ArticleId>\n            <ArticleId IdType=\"pmc\">4513941</ArticleId>\n            <ArticleId IdType=\"doi\">10.1056/NEJMoa1306220</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586‚Äì90.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">26275952</ArticleId>\n            <ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-14-2225</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41(24):3988‚Äì97.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">37192437</ArticleId>\n            <ArticleId IdType=\"pmc\">10461952</ArticleId>\n            <ArticleId IdType=\"doi\">10.1200/JCO.23.00562</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">33801659</ArticleId>\n            <ArticleId IdType=\"pmc\">8037248</ArticleId>\n            <ArticleId IdType=\"doi\">10.3390/ijms22073464</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15(8):1781‚Äì91.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">27413114</ArticleId>\n            <ArticleId IdType=\"doi\">10.1158/1535-7163.MCT-15-0945</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Armstrong SA, Schultz CW, Azimi-Sadjadi A, Brody JR, Pishvaian MJ. ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications. Mol Cancer Ther. 2019;18(11):1899‚Äì908.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">31676541</ArticleId>\n            <ArticleId IdType=\"pmc\">6830515</ArticleId>\n            <ArticleId IdType=\"doi\">10.1158/1535-7163.MCT-19-0208</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Estivill X, Armengol L. Copy number variants and common disorders: filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet. 2007;3(10):1787‚Äì99.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">17953491</ArticleId>\n            <ArticleId IdType=\"doi\">10.1371/journal.pgen.0030190</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Mokhtar SS, Marshall CR, Phipps ME, Thiruvahindrapuram B, Lionel AC, Scherer SW, Peng HB. Novel population specific autosomal copy number variation and its functional analysis amongst Negritos from Peninsular Malaysia. PLoS ONE. 2014;9(6): e100371.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">24956385</ArticleId>\n            <ArticleId IdType=\"pmc\">4067311</ArticleId>\n            <ArticleId IdType=\"doi\">10.1371/journal.pone.0100371</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Ionita-Laza I, Laird NM, Raby BA, Weiss ST, Lange C. On the frequency of copy number variants. Bioinformatics. 2008;24(20):2350‚Äì5.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">18689430</ArticleId>\n            <ArticleId IdType=\"pmc\">2562008</ArticleId>\n            <ArticleId IdType=\"doi\">10.1093/bioinformatics/btn421</ArticleId>\n          </ArticleIdList>\n        </Reference>\n        <Reference>\n          <Citation>Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, et al. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. J Natl Cancer Inst. 2016;108(4):djv362.</Citation>\n          <ArticleIdList>\n            <ArticleId IdType=\"pubmed\">26598514</ArticleId>\n            <ArticleId IdType=\"doi\">10.1093/jnci/djv362</ArticleId>\n          </ArticleIdList>\n        </Reference>\n      </ReferenceList>\n    </PubmedData>\n  </PubmedArticle>\n</PubmedArticleSet>\n\n","output_type":"stream"}],"execution_count":18}]}